152 results on '"Fumery M"'
Search Results
2. P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study
3. P386 Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UC-RGENCY study
4. DOP05 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s Disease
5. P943 Real world Effectiveness and safety of tofacitinib in patients with Ulcerative Colitis: 6 months follow-up of the French TOFAST study
6. P408 Complete endoscopic healing, the future therapeutic target in Crohn's disease? Results of a prospective multicenter study
7. P1151 Incidence and risk factors of thromboembolic events in Pediatric-Onset Inflammatory Bowel Disease: a population-based study
8. P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study
9. P275 Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of Crohn’s disease
10. P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
11. P322 Compared Efficacy of Second-Line Treatments for Ulcerative Colitis After Failure of Vedolizumab in First-Line Treatment: A Retrospective Multicenter Study
12. P360 Prevalence and risk factors for fatigue in patients with inflammatory bowel disease and endoscopic healing
13. DOP79 Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort
14. P1015 Subcutaneous infliximab effectively manages clinical outcomes of Inflammatory Bowel Disease independently of various confounding factors
15. P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial
16. P318 Performance of rectosigmoidoscopy and rectoscopy to assess endoscopic and histological healing in ulcerative colitis
17. DOP23 The role of histology for the prediction of clinical relapse in Crohn’s Disease: A substudy of the STORI cohort
18. P733 Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT study
19. P226 Disability in Crohn’s Disease Patients at diagnosis: Findings from the CROCO (Crohn´s Disease Cohort) study
20. P1122 Comorbidities Associated with Pediatric Onset Inflammatory Bowel Diseases: A Population-Based Study
21. P1125 Incidence and Neoplastic Risk Associated with Colonic Stricture in Pediatric-Onset Crohn's Disease: A Population-based Study
22. P231 Impact of the depth of mucosal healing on the burden of ulcerative colitis : a cross-sectional study
23. P712 Effectiveness of switching from intravenous to subcutaneous infliximab in Inflammatory Bowel Disease patients: A combined analysis of real-world evidence
24. Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study.
25. Disease course of Crohn's disease during the first ten years following diagnosis in a prospective European population-based inception cohort - the Epi-IBD cohort
26. Disease course of Ulcerative Colitis during the first ten years following diagnosis in a prospective European population-based inception cohort - the Epi-IBD cohort
27. P435 Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS study
28. P450 Real life Effectiveness and safety of an induction treatment with tofacitinib in patients with Ulcerative Colitis: First results of the French TOFAST cohort
29. P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study
30. P338 Transmural healing is not associated with less disability than complete endoscopic mucosal healing: a prospective study in a patient with Crohn's disease
31. P299 Disability in newly diagnosed patients with Crohn′s Disease: initial results from the prospective CROCO (Crohn′s Disease Cohort) Study
32. P130 Intestinal ultrasound combined to fecal calprotectin is effective to predict endoscopic mucosal healing in ulcerative colitis: a cross-sectional study
33. DOP45 Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
34. P155 Natural history of anal stricture in pediatric-onset Crohn’s disease: a two-decades population-based study
35. P876 Disease course of Inflammatory Bowel Disease Unclassified in adult patients : a population-based study (1988-2014)
36. P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study
37. P303 Ultrasound is effective to identify mucosal healing in Crohn's disease patients : results of a cross-sectional study
38. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study
39. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study
40. P624 Long-term effectiveness of anti-TNF therapy in pediatric-onset inflammatory bowel diseases: a population-based study
41. P119 Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series
42. DOP76 Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent
43. P142 Inflammatory bowel diseases associated with primary immunodeficiency: a multicenter study
44. OP35 Natural history of anal ulcerations in pediatric-onset Crohn’s Disease: A population-based study
45. P393 Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for acute severe colitis
46. P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?
47. DOP33 Role of adherent and invasive E. coli in Crohn’s Disease: Lessons from the postoperative recurrence model
48. DOP34 Comparison of the risk of clinical recurrence after ileocolonic resection for Crohn’s Disease for modified Rutgeerts’ score i2a and i2b categories: Individual patient data meta-analysis
49. P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study
50. P558 Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.